Tenax Therapeutics (TENX) Income from Continuing Operations: 2011-2024
Historic Income from Continuing Operations for Tenax Therapeutics (TENX) over the last 11 years, with Dec 2024 value amounting to -$17.6 million.
- Tenax Therapeutics' Income from Continuing Operations fell 183.07% to -$34.3 million in Q4 2016 from the same period last year, while for Dec 2016 it was -$56.6 million, marking a year-over-year increase of 57.81%. This contributed to the annual value of -$17.6 million for FY2024, which is 126.43% down from last year.
- Tenax Therapeutics' Income from Continuing Operations amounted to -$17.6 million in FY2024, which was down 126.43% from -$7.8 million recorded in FY2023.
- In the past 5 years, Tenax Therapeutics' Income from Continuing Operations registered a high of $11.0 million during FY2022, and its lowest value of -$17.6 million during FY2024.
- Its 3-year average for Income from Continuing Operations is -$4.8 million, with a median of -$7.8 million in 2023.
- Data for Tenax Therapeutics' Income from Continuing Operations shows a maximum YoY crashed of 170.36% (in 2023) over the last 5 years.
- Tenax Therapeutics' Income from Continuing Operations (Yearly) stood at -$9.9 million in 2020, then reached $11.0 million in 2022, then tumbled by 170.36% to -$7.8 million in 2023, then tumbled by 126.43% to -$17.6 million in 2024.